AbbVie Inc. v. Federal Trade Commission
Petition for certiorari denied on June 21, 2021. Justice Alito took no part in the consideration or decision of this petition.
Issue
Whether the subjective element of the "sham litigation" exception to Noerr-Pennington immunity may be met by an inference from a finding that a challenged lawsuit was objectively baseless, even without evidence that the antitrust defendant actually believed the suit lacked merit or was indifferent to the outcome.
Mar 18, 2021Petition for a writ of certiorari filed. (Response due April 19, 2021)Apr 15, 2021Motion to extend the time to file a response from April 19, 2021 to May 19, 2021, submitted to The Clerk.
Apr 16, 2021Motion to extend the time to file a response is granted and the time is extended to and including May 19, 2021.
Apr 19, 2021Brief amicus curiae of Chamber of Commerce of the United States of America filed.Apr 19, 2021Brief amici curiae of Law Professors filed.Apr 19, 2021Brief amici curiae of Pharmaceutical Research and Manufacturers of America and Biotechnology Innovation Organization filed.May 19, 2021Brief of respondent United States in opposition filed.May 28, 2021Letter waiving the 14-day waiting period for the filing of a reply pursuant to Rule 15.5 filed.Jun 1, 2021DISTRIBUTED for Conference of 6/17/2021.
Jun 1, 2021Reply of petitioners AbbVie Inc., Abbott Laboratories, Unimed Pharmaceuticals LLC, and Besins Healthcare, Inc. filed. (Distributed)Jun 21, 2021Petition DENIED. Justice Alito took no part in the consideration or decision of this petition.
Recommended Citation: AbbVie Inc. v. Federal Trade Commission, SCOTUSblog, https://www.scotusblog.com/cases/abbvie-inc-v-federal-trade-commission/